Qube Research & Technologies (QRT)
AMLX icon

Qube Research & Technologies (QRT)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.2M Sell
681,389
-20,847
-3% -$322K 0.01% 1178
2026
Q1 		$9.76M Buy
702,236
+289,363
+70% +$4.07M 0.01% 1298
2025
Q4 		$4.99M Buy
412,873
+245,767
+147% +$3.34M 0.01% 1770
2025
Q3 		$2.27M Sell
167,106
-270,920
-62% -$2.55M ﹤0.01% 2181
2025
Q2 		$2.81M Sell
438,026
-504,865
-54% -$2.46M ﹤0.01% 2034
2025
Q1 		$3.34M Buy
942,891
+162,325
+21% +$578K ﹤0.01% 1740
2024
Q4 		$2.95M Buy
780,566
+596,672
+324% +$2.81M ﹤0.01% 1723
2024
Q3 		$596K Sell
183,894
-605,233
-77% -$1.36M ﹤0.01% 2207
2024
Q2 		$1.5M Sell
789,127
-154,936
-16% -$300K ﹤0.01% 1742
2024
Q1 		$2.68M Buy
944,063
+461,464
+96% +$6.04M ﹤0.01% 1588
2023
Q4 		$7.1M Buy
482,599
+319,889
+197% +$4.9M 0.01% 876
2023
Q3 		$2.98M Buy
162,710
+38,530
+31% +$815K 0.01% 1180
2023
Q2 		$2.68M Buy
124,180
+92,455
+291% +$2.5M 0.01% 930
2023
Q1 		$931K Buy
+31,725
New +$1.1M ﹤0.01% 1319

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AMLX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) reduced its Amylyx Pharmaceuticals (AMLX) stake by 3% in Q2 2026, selling an estimated $322K and leaving 681,389 shares worth $12.2M. The position accounts for 0.01% of the portfolio, ranked #1178.

Qube Research & Technologies (QRT) first reported a position in AMLX in Q1 2023 and has held it in 14 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Qube Research & Technologies (QRT) held 681,389 shares of Amylyx Pharmaceuticals worth $12.2M as of Q2 2026.
  • Qube Research & Technologies (QRT) sold 20,847 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $322K.
  • Amylyx Pharmaceuticals made up 0.01% of Qube Research & Technologies (QRT)'s portfolio in Q2 2026, its #1178 holding.
  • Qube Research & Technologies (QRT) first reported a position in Amylyx Pharmaceuticals in Q1 2023 and has held it in 14 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.